Background: Inhaled corticosteroids (ICSs) reduce local airway inflammation, which is an underlying cause of asthma symptoms. However, potential systemic side effects associated with ICS use are a major concern for asthmatic patients. 
guidelines advocate the early introduction and sustained use of ICSs in asthmatic adults and children. 2, 3, 7 ICSs at recommended doses are generally safe, but the availability of newer more potent forms, the advent of chlorofluorocarbon (CFC)-free formulations that deliver the drug more effectively, and the trend toward higher and longer dosing have contributed to concerns regarding the safety of long-term treatment. 8 -12 Known adverse effects of ICSs in-
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clude oropharyngeal candidiasis and dysphonia, and the more serious systemic effects of adrenal insufficiency, Cushing syndrome, osteoporosis and bone fracture, posterior subcapsular cataracts, skin bruising, and possibly decreased growth velocity. 13, 14 The systemic activity of corticosteroids, and their potential for adverse systemic effects, are generally assessed by the degree to which they cause hypothalamic-pituitary-adrenal (HPA)-axis suppression. 9, 15, 16 Ciclesonide (CIC), the newest generation of ICSs, is inhaled as an inactive parent compound, which is then hydrolyzed to its active form, desisobutyryl-CIC (des-CIC). CIC has been designed to have several favorable pharmacokinetic characteristics such as low oral bioavailability, rapid clearance, and high serum protein binding that would limit systemic exposure and side effects, while maintaining potent glucocorticoid receptor-binding activity in the lung. [17] [18] [19] [20] [21] Des-CIC, with a receptor-binding affinity 12 times that of dexamethasone, has one of the highest receptor-binding affinities for an ICS (relative receptor affinity, 1,200). 22 In addition, CIC is administered using a metered-dose inhaler (MDI) in a solution of hydrofluoroalkane (HFA) propellant, which allows for the production of small, highly respirable particles, which result in a significant percentage (Ͼ50%) of the administered dose being topically deposited in the lungs. 22, 23 The present study investigated the potential effects of CIC at doses of 320 and 640 g bid on HPA-axis function in patients with moderate-to-severe asthma. This is the first study to examine the effects of high doses of CIC for a prolonged duration (4 weeks) in patients with moderateto-severe asthma. The overall study design was similar to that of the study of Affrime et al 24 and was double-blind, parallel, and placebo (PBO)-controlled. Treatment was administered for 4 weeks and included fluticasone propionate (FP) [440 and 880 g bid using an MDI-CFC] as an active comparator. The primary evaluation of HPA-axis function was the measurement of serum cortisol area under the curve for 0 to 24 h (AUC 0 -24h ). Additional evaluations were the determination of the serum cortisol response to low-dose (1 g) cosyntropin and the measurement of 24-h urinary cortisol levels corrected for creatinine.
Subjects and Methods

Study Population
The study population consisted of nonsmoking male and female adults (Ն 18 years of age) who had a Ն 3-month history of moderate-to-severe persistent asthma (FEV 1 , Ն 40% and Յ 80% of predicted). To be eligible, patients had to demonstrate at least a 12% reversibility of FEV 1 following two inhalations of albuterol (or a documented history of at least a 12% reversibility within 1 year). In addition, patients had to demonstrate normal HPA-axis function, which was defined as a basal am serum cortisol level of Ն 5 g/dL and a serum cortisol level of Ն 18 g/dL at one or more of the following time points following the administration of low-dose (1 g) synthetic adrenocorticotrophic hormone (ACTH) cosyntropin (Cortrosyn; Organon Pharmaceuticals; Roseland, NJ): 20 min; 30 min; or 60 min. Women receiving oral contraceptives or hormone replacement therapy were also required to have an increase in serum cortisol levels of Ն 7 g/dL from basal to peak levels. Oral contraceptives (OCs) and hormone replacement therapy are known to bind to cortisol-binding globulin, 8 and the plasma cortisol concentration is approximately twice as high in women who are receiving an oral contraceptive than in those who are not. 25 Additionally, patients had to demonstrate that they could properly use an oral inhaler.
Patients were excluded from the study if they had a documented history of drug or alcohol abuse, had used ICSs, intranasal steroids, or ICSs in combination with long-acting bronchodilators within 3 months prior to screening, had used systemic corticosteroids within 3 months prior to screening or any investigational drug within 30 days prior to screening, or had used concomitant medications that were expected to interfere with the interpretation of study data. Any patient with a history of cardiovascular, pulmonary, neurologic, hepatic, renal, or any significant acute or chronic illness was also excluded. Patients who had oral candidiasis within 30 days prior to screening and female patients who were pregnant or lactating were excluded from the study.
Study Design
This was a single-center, randomized, double-blind, doubledummy, multiple-dose, parallel-group trial comparing the effects of CIC (R-CIC; Aventis Pharmaceuticals; Bridgewater, NJ), FP (Flovent; GlaxoSmithKline; Research Triangle Park, NC), and PBO on HPA-axis function in adult asthmatic patients with normal am cortisol values at screening (Fig 1) . The baseline period encompassed visits 1 to 3 (ie, days Ϫ14 to Ϫ9, days Ϫ10 to Ϫ7, and day Ϫ1). Double-blind treatment visits occurred at day 1 (randomization), day 8 (week 1), day 15 (week 2), day 22 (week 3), day 29 (week 4), and day 30 (hospital discharge). At visits 1 and 2 (prescreening and screening, days Ϫ14 to Ϫ7), adult patients with moderate-to-severe persistent asthma were assessed for eligibility to enter the study. Those meeting the inclusion criteria were classified as eligible patients (n ϭ 60) on day Ϫ1 (visit 3), were admitted to the clinic as inpatients, and were randomized (day 1) to receive one of the following five treatments for 29 days: CIC, 320 g bid (CIC 640); CIC, 640 g bid (CIC 1280); FP, 440 g bid (FP 880); FP, 880 g bid (FP 1, 760) [all doses are expressed as ex-actuator and were comparable to ex-valve doses of 800 and 1,600 g/d for CIC and 1000 and 2000 g/d for FP, respectively]; or PBO. Treatments were administered via MDI with an HFA-134a propellant for CIC (MDI canisters delivering 80 and 160 g per puff) and a CFC propellant for FP (MDI canisters delivering 110 and 220 g per puff). Each patient was provided with two MDI canisters of study medication in a blinded manner (ie, double-dummy) at randomization with at least one of the canisters being a PBO. Patients were to inhale four puffs from each MDI in the morning (at 8:00 to 8:30 am) and four puffs in the evening (at 8:00 to 8:30 pm). Albuterol canisters were provided to the patients as rescue medication.
Patient compliance was assessed by canister weight and patient diaries. All study medication was administered under the direct supervision of the investigator/coordinator to confirm that the proper dose was taken and the proper inhalation technique was used. A patient was considered to be compliant on a given day if they took the study medication as per the protocol for that day (total, 16 puffs per day; ie, 4 puffs from each of the two canisters in the morning and 4 puffs from each of the two canisters in the evening). The overall percentage of compliance was defined as the percentage of compliant study days of all study days.
The investigation was conducted in accordance with the good clinical practice guidelines established by the International Conference on Harmonization in conformity with the Declaration of Helsinki. The clinical study protocol and informed consent documents were reviewed and approved by an independent ethics committee/institutional review board. Informed consent was obtained from all patients prior to conducting any studyrelated procedures. The safety of the various drug treatments was examined using clinical pharmacodynamic evaluations of HPAaxis function, laboratory results, and emergent adverse events due to treatment.
Pharmacodynamic Outcomes
Serum Cortisol AUC 0 -24h : The primary outcome was the change from baseline to day 29 in the serum cortisol concentration AUC 0 -24h . Twenty-four-hour serum cortisol levels were determined on day Ϫ1 (baseline period, prior to randomization) and at days 8, 15, 22, and 29. Blood samples (approximately 2.5 mL) were collected and analyzed from patients over 24 h at 8:00 am, 9:00 am, 10:00 am, 12:00 pm, 2:00 pm, 4:00 pm, 6:00 pm, 8:00 pm, and 10:00 pm of one day, and 12:00 am, 2:00 am, 4:00 am, 6:00 am, 7:00 am, and 8:00 am of the following day. Serum was isolated from each sample by centrifugation (1500g for 10 min), and cortisol was measured by electrochemiluminescence immunoassay (Elecsys Cortisol kit; Roche Diagnostics; Indianapolis, IN) at a central laboratory (Covance Central Laboratory Services; Indianapolis, IN). Briefly, the sample was incubated with a cortisol-specific biotinylated antibody and a ruthenium complexlabeled cortisol derivative. On the addition of streptavidin-coated microparticles, the complex was bound to a solid phase via interactions of both biotin and streptavidin. The microparticles were then magnetically captured on the surface of an electrode; the application of a voltage produced a chemiluminescent signal. The lower limit of quantitation of the assay was to 0.3 g/dL; the intra-assay precision was 1.0 to 1.4% coefficient of variation, and the inter-assay precision was 2.1 to 5.4% CV. Serum cortisol AUC 0 -24h values were calculated using the trapezoidal rule for numerical integration using the actual recorded collection times.
1 g of Cosyntropin-Stimulated Serum Cortisol: One of the secondary outcomes was serum cortisol measurements obtained after low-dose (1 g) cosyntropin stimulation. The cosyntropin test was conducted during the screening period and at day 30 (or early termination). Serum cortisol measurements were obtained 15 min prior to the administration of cosyntropin. Subsequently, 1 g of cosyntropin was injected as a 1-mL bolus between 8:00 am and 8:15 am. Blood samples were collected at 20, 30, and 60 min after the cosyntropin injection. The peak cortisol level was defined as the highest of the three measured serum cortisol levels. Cortisol levels in response to cosyntropin were also determined by electrochemiluminescence immunoassay.
24-h Urinary Cortisol Level:
Another secondary outcome was the change from baseline to day 29 (or early termination) in 24-h urinary free cortisol level corrected for creatinine (in micrograms per milligram creatinine). Patients were required to completely empty their bladders prior to the start of urine collection, and then collect all subsequent urine for 24 h. Urine samples were analyzed using high-performance liquid chromatography with an ultraviolet detector. Briefly, the sample was treated with methanol to extract the cortisol and to precipitate proteins, and an internal standard was added. Following solid-phase extraction through a C18 cartridge and elution with dichloromethane, the sample was dried down, reconstituted with mobile phase, and injected onto a reverse-phase ODS column. The lower limit of quantitation was 0.50 g/dL, the intraassay precision was 2.2 to 4.6% CV, and the interassay precision was 4.7 to 5.5% CV.
Safety Analysis
Safety evaluations were based on the following: (1) physical examination results, vital signs, body weight, and clinical laboratory safety values obtained during the screening period and at day 30 (or early study termination); (2) oropharyngeal examination (if a fungal infection of the mouth or throat was suspected, a culture was to be taken and sent to the central laboratory for testing to confirm the diagnosis by either symptoms or direct examination) results obtained at baseline and at days 1, 8, 22, and 30 (or early study termination); and (3) adverse events, recorded throughout the study and until 14 days after the last dose of the study drug. Hematology, serum chemistry, and urinalysis tests were carried out according to standard methodologies. All blood assays for laboratory safety and efficacy variables were conducted by one company (Covance Central Laboratory Services). 
Statistical Analysis
The primary population for all pharmacodynamic analyses was the intent-to-treat population. This population included all randomized patients who had received at least one dose of study medication and who had a valid baseline measurement and at least one valid postbaseline measurement of the primary analysis variable (ie, serum cortisol AUC 0 -24h ). The serum cortisol AUC 0 -24h was considered to be valid if each of the following time intervals contained at least one actual collection time of a nonmissing cortisol measurement: 7:30 am to 8:30 am; 9:30 am to Ͻ 2:00 pm; 2:00 pm to Ͻ 6:00 pm; 6:00 pm to Ͻ10:00 pm; 10:00 pm to Ͻ 2:00 am; 2:00 am to 6:30 am: 7:30 am to 8:30 am.
Demographic and baseline characteristics were summarized by treatment group and overall to assess the comparability of the five treatment groups at baseline. Continuous data were summarized using summary statistics, including the number of patients, and the mean, SD, median, minimum, and maximum values. The data for categoric variables were summarized using frequency distributions. Baseline variables were tested for among-treatment heterogeneity. The baseline imbalance for continuous variables was assessed using a nonparametric analysis of variance model with a parameter for treatment, modeled as a fixed effect. The nonparametric analysis of variance was performed by ranking the response variable without regard to treatment classification. Baseline imbalance for categoric variables was compared among treatment groups using a Cochran-Mantel-Haenszel test.
The primary analysis of change from baseline in primary and secondary variables at the end of the study was conducted using an analysis of covariance (ANCOVA) method. The ANCOVA model included such factors as age, sex, baseline FEV 1 , and serum cortisol AUC 0 -24h as covariates. Pairwise comparisons were based on least-squares estimates and SE values from the above primary analysis model (␣ ϭ 0.05 was the threshold for statistical significance for these comparisons). Two-sided 95% confidence intervals (CIs) for the treatment difference were constructed for each treatment comparison. Based on data from the study by Affrime et al, 24 and assuming an SD of 50 g⅐hr/dL and a mean PBO of 230 g⅐hr/dL for the change from baseline in serum cortisol AUC 0 -24h after 4 weeks of treatment, the following calculation was used: with a sample size of 12 patients per treatment group (60 patients total), the study would have 90% power (at ␣ ϭ 0.05, two-sided test) to detect a difference of approximately 30 percentage points with respect to mean PBO in the change from baseline in serum cortisol AUC 0 -24h between the two treatment groups.
Results
Patient Disposition and Demographics
A total of 77 subjects with at least a 3-month history of moderate-to-severe persistent asthma and normal HPA-axis function were screened to participate in the study. Sixty subjects met the eligibility requirements and were randomized (12 per group) to double-blind treatment with CIC 640, CIC 1280, FP 880, FP 1760, or PBO. Seventeen patients were not randomized due to a failure to meet cosyntropin entry criteria (n ϭ 10), a failure to meet FEV 1 entry criteria (n ϭ 4), withdrawal of consent (n ϭ 2), or smoking (n ϭ 1). All randomized patients received at least one dose of study medication and completed the entire 29 days of treatment. Since all patients completed the study, future reference will be to "end-of-study" values.
There were no statistically significant differences in demographic characteristics among the groups at baseline (Table 1) . Only 8 of the 33 female patients (of a total of 60 patients) randomized to the five groups were using OC or HRT at baseline.
Patient Compliance
Fifty-nine of 60 patients were 100.0% compliant with therapy. One patient in the FP 1760 group missed a day and a half of treatment and had an overall compliance rate of 93.3%. 
Pharmacodynamics
Mean Serum Cortisol AUC 0 -24h : The baseline mean serum cortisol AUC 0 -24h values were comparable in all CIC and FP treatment groups, although the PBO group displayed a nonsignificantly higher value due to the inclusion of three patients with mean serum cortisol AUC 0 -24h of Ͼ300 g⅐h/dL (Table 2) .
At the end of the study, there was no significant change from baseline in the mean serum cortisol AUC 0 -24h values for the PBO, CIC 640, CIC 1280, and FP 880 groups (Table 2 ). In the FP 1760 group, the mean serum cortisol AUC 0 -24h (adjusted) was significantly lower at the end of the study compared with baseline. Since the 95% CI for the difference between the day 29 and baseline values did not contain 0 (Ϫ107.1 to Ϫ49.1), this was a statistically significant effect. The mean change in serum cortisol AUC 0 -24h in the FP 1760 group at day 29 was also significantly different from that of the PBO group (p ϭ 0.0009; 95% CI, Ϫ117.5 to Ϫ32.1) and the CIC 1280 group (p ϭ 0.0013; 95% CI, 28.3 to 110.0) [ Table 2 ]. Further, in the FP 1760 group there were more patients with reductions in serum cortisol AUC 0 -24h based on threshold evaluations (Table 3) .
The changes in mean serum cortisol AUC 0 -24h in patients receiving CIC 640, CIC 1280, and FP 880 were not significantly different from those in patients receiving PBO at any time point in the trial. By comparison, the reduction in mean serum cortisol AUC 0 -24h with FP 1760 was statistically significant at all time points and increased with time of treatment (Fig 2) .
In order to examine serum cortisol AUC 0 -24h independent of differences in baseline values, changes in this parameter at 29 days of treatment were expressed as the percentage change from baseline (Fig 3) . At 29 days, the percentage change in serum cortisol AUC 0 -24h in the CIC groups was not significantly different from that of the PBO group (CIC 640, p ϭ 0.5901; CIC 1280, p ϭ 0.7760). The percentage change in serum cortisol AUC 0 -24h in the FP 1760 group was significantly different from that of the PBO group (p Ͻ 0.01). In addition, the percentage change in serum cortisol AUC 0 -24h for the FP 1760 group was significantly different from those of the CIC 640, CIC 1280, and FP 880 groups (p Ͻ 0.01).
g of Cosyntropin-Stimulated Serum Cortisol:
Peak cortisol was defined as the highest of the three serum cortisol levels measured at 20, 30, and 60 min after stimulation with 1 g of cosyntropin. At baseline, precosyntropin and peak cosyntropin-stimulated cortisol levels were similar in the five treatment groups (Table 4, Fig 4, top) . In the FP 1760 group, there was a decrease in the adjusted mean change from baseline. However, as indicated by the 95% CIs, none of the treatments produced a statistically significant change in the peak serum cortisol response vs baseline values (Table 4 ; Fig 4, middle) . The degree of stimulation (ie, cosyntropin value Ϫ precosyntropin value) at baseline and following 29 days of treatment was also determined. All treatments resulted in increases in the mean degree of cosyntropin stimulation at the end of the study vs baseline; however, none of the changes were statistically significant among the treatments (Fig 4,  bottom) .
24-h Urinary Cortisol:
The mean (Ϯ SD) urine volume collected was 1,828.8 Ϯ 561.1 mL. None of the treatment groups showed a statistically signifi- cant decrease in 24-h urinary cortisol levels from baseline at day 29 as compared to PBO. However, there was a statistically significant increase in urinary cortisol levels in the CIC 640 group compared to the PBO group (p ϭ 0.0224; 95% CI, 0.0023 to 0.0283) [Fig 5] .
Safety
The incidence of treatment-emergent adverse events was similar in the five treatment groups, and all adverse events were classified as mild or moderate in severity ( Table 5 ). The body system with the highest overall incidence of events was the nervous system (33 to 50% in the different treatment groups) with headache being the most frequently reported event and the only event classified as possibly treatment-related. The percentage of patients with possibly treatment-related headache varied among treatment groups, ranging from 8.3% with CIC 640 to 41.7% with FP 880 and PBO. There were no serious adverse events. The mean baseline values for routine laboratory test results were similar across all treatment groups. The mean changes from baseline to the end of the study in laboratory values were small and not clinically significant for all study groups.
Discussion
ICSs are generally accepted as first-line therapy for the long-term treatment of asthma. 2, 3 Patients having severe asthma typically receive high daily doses of ICSs for extended periods of time. 2, 3, 7 Therefore, the known adverse events associated with ICSs have particular importance in this patient population.
CIC is a novel ICS that has a number of features designed to decrease local (oropharyngeal) and systemic side effects, while maintaining high antiasthmatic activity. [17] [18] [19] [20] [21] CIC is administered in solution via an MDI inhaler using HFA-134a as a propellant, with particle sizes of 1.1 to 2.1 m, 22 thus optimizing lung deposition and limiting oropharyngeal deposition. 26 CIC itself is an inactive parent compound that to a large extent is converted on-site within the lung to its active moiety des-CIC, but is only minimally converted to des-CIC in the oropharynx. 27, 28 Des-CIC has excellent antiinflammatory properties by virtue of its high binding coefficient with glucocorticoid receptors. 29 Des-CIC is esterified in the target tissue, forming a storage molecule that may be retained within the lung for extended periods, 30 which may contribute to once-daily dosing. Both CIC and des-CIC possess high protein binding and rapid clearance. 22, 31, 32 Additionally, the oral bioavailability (due to the swallowed portion of the inhaled dose) of CIC and des-CIC is Ͻ 1%. 22, 32 CIC has been shown to be safe and effective in the treatment of persistent asthma. In randomized, PBO-controlled trials, treatment at doses up to 640 g/d improved lung function and asthma symptoms, decreased airway hyperresponsiveness, and reduced the use of rescue medication. 5, 19, [33] [34] [35] [36] The doses of ICSs evaluated in the present study were based on previous clinical trial experience with CIC and the approved dosing for FP. Doses of CIC ranging from 80 to 1,280 g/d have been evaluated in US phase III studies of asthmatic patients. The highest dose of CIC in this study (1,280 g/d) was twice the highest dose evaluated in US phase III safety and efficacy trials in patients with severe asthma who were not dependent on oral corticosteroids (OCS), and was equal to the higher of two doses examined in OCSdependent patients (640 and 1,280 g/d). Treatment guidelines for adults 2,3 recommend high-doses of ICSs (Flovent dose, Ͼ 660 g/d) for severe persistent asthma and low-to-medium doses of ICSs (Flovent dose, 264 to 660 g/d) for moderate persistent asthma. The FP dose of 880 g bid is the highest dose that has been approved for use and is recommended for patients with severe asthma who are dependent on OCS. 37 Additionally, it has been shown that at the lower dose range, a CIC dosage of 160 g qd was shown to have an effect on FEV 1 that was similar to that of an FP dosage of 88 g bid. 38 Assessments of HPA-axis function have been used to evaluate the potential for systemic side effects of ICSs. 9, 15, 16 The present study evaluated the potential effects of 4 weeks of treatment with CIC on HPAaxis function in patients with moderate-to-severe asthma. The primary evaluation of HPA-axis function in this study was the change in serum cortisol AUC 0 -24h . The study was statistically powered to detect differences between active treatment groups and the PBO group in terms of the change from baseline in serum cortisol AUC 0 -24h . The FP CFC-MDI formulation, rather than the FP HFA-MDI formulation, was used as an active comparator. At the time of this study, the FP HFA-MDI formulation was not available in the United States.
Patients receiving CIC, 640 g/d, CIC, 1,280 g/d, and FP, 880 g/d, had mean serum cortisol AUC 0 -24h levels that were unchanged from baseline (results are within the limits of variability) and were similar to that in the PBO group, while patients treated with high-dose FP (1,760 g/d) had significantly suppressed serum cortisol AUC 0 -24h values. The results obtained with low-dose cosyntropin stimulation and 24-h urinary cortisol levels corrected for creatinine showed no statistically significant HPAaxis suppression with any of the active treatments, although high-dose FP was the only treatment that produced a negative mean change from baseline in peak cortisol with the cosyntropin test.
The observed results with CIC were consistent with those of several previous studies 20,35,36,39 -41 conducted in healthy subjects as well as in asthmatic subjects that have demonstrated that CIC does not suppress HPA-axis function. In a PBO-controlled crossover study 20 of 12 healthy subjects, CIC, 640 g/d, administered once daily (am or pm) or 320 g twice daily for 7 days, did not change the 24-h serum cortisol profile. In the PBO-controlled crossover study conducted by Derom and coworkers 36 in 26 asthmatic patients, the same daily doses of CIC and FP were administered as in the present study, but for 9 days rather than 4 weeks. None of the doses of CIC suppressed plasma cortisol AUC 0 -24h or 24-h urinary cortisol levels, whereas both doses of FP suppressed these parameters. No influence on urinary cortisol has been observed following a single dose of CIC, 2,880 g/d, and the cortisol profile for doses of 400 and 1,600 g/d for 1 week were equivalent to that for PBO. 42 Moreover, a pooled analysis of CIC at doses of up to 2,880 g/d in healthy volunteers and patients with asthma showed minimal effects on adrenal function. 31 The finding that FP, 880 g/d, did not cause HPA-axis suppression is consistent with those of some previous studies, 40, 43 although several studies 9, 12, 16, 24, 36, 44, 45 have demonstrated HPA-axis suppression with this and/or lower doses of FP. In patients with moderate-to-severe asthma, factors such as airflow obstruction and ventilation perfusion mismatch can alter drug deposition in the lungs and change systemic absorption. A reduced airway caliber has been shown to reduce the lung bioavailability of FP 44, 46 ; it is known that the systemic bioavailability of inhaled FP is more than halved in asthmatic patients compared to healthy control subjects. 46 The patient population in this trial consisted of patients with moderate-to-severe asthma, with a mean FEV 1 percent predicted that ranged from 56.2 to 64.8% at baseline. This phenomenon might also explain the lack of adrenal suppression with the lower dose of FP in the present study.
The suppression of serum cortisol AUC 0 -24h observed in patients receiving FP, 1,760 g/d, was expected. This dose is known to cause the suppression of the HPAaxis 13, 24, 47 and has been used previously in other studies as an active comparator. 24, 36 The study by Affrime et al, 24 in which one of the component studies had a similar parallelgroup design, compared the effects of FP, 1,760 g/d, mometasone furoate, MDI 800 and 1,600 g/d, and PBO on the HPA axis. Statistically significant suppression of plasma cortisol AUC 0 -24h was found after the administration of FP, 1,760 g/d, and mometasone furoate, 1,600 g/d. A recent study 48 of patients with moderate persistent asthma evaluated the effects of CIC, 1,280 g/d, and FP, 1,760 g/d, on the plasma cortisol response to human corticotrophin-releasing factor. Serum cortisol, both prior to and in response to human corticotrophin-releasing factor, was suppressed from baseline by FP, 1,760 g/d, in contrast to CIC, 1,280 g/d, which did not. The overnight *TEAE ϭ treatment-emergent adverse event; NOS ϭ not otherwise specified. 10-h urinary cortisol level was also suppressed by FP, 1,760 g/d, but not by CIC, 1,280 g/d.
The dissociation in effects on basal HPA-axis function (assessed by serum cortisol AUC 0 -24h ) and dynamic HPA-axis function (assessed by low-dose cosyntropin stimulation) observed in the present study might be explained by the much longer treatment periods required to produce adrenocortical atrophy and reduced adrenal reserve, whereas the effects on basal adrenocortical secretion can be seen even after single dosing. Similar discordant results have been reported previously for FP and other ICSs. 24, 49, 50 Additionally, compared to integrated serum cortisol measurements, 24-h urinary cortisol measurements may have greater variability and be less reliable in assessing changes in HPA-axis function. 9, 16 However, both the low-dose cosyntropin stimulation and 24-h urinary cortisol measurements are sensitive markers of HPA-axis suppression, and the 1-month duration should have been long enough to produce suppression of the ACTH response. One explanation for this is that while the suppression of serum cortisol AUC 0 -24h for the higher dose of FP was statistically significant, it may not be clinically relevant if it did not produce a commensurate suppression of the ACTH-stimulated cortisol response.
Previous studies have shown comparable efficacy and potency for CIC and FP in reducing airway responsiveness, and in improving pulmonary function and asthma symptoms. In the PBO-controlled crossover study conducted by Derom and coworkers 36 in 26 asthmatic patients, all doses of CIC (320 g qd, 640 g qd, and 640 g bid) and both doses of FP (440 g bid and 880 g bid by CFC-MDI) decreased hyperresponsiveness to adenosine monophosphate, as demonstrated by a more than doubling of the dose yielding a provocative concentration causing a fall of 20% in FEV 1 , although no dose response was demonstrated for any of the two steroids. In a double-blind crossover study 51 conducted in 19 mild-to-moderate asthma patients, there was no significant difference after 4 weeks of treatment with CIC, 320 qd, or FP, 210 g bid (administered by HFA-MDI), in reducing hyperresponsiveness to methacholine. In another doubleblind study, 38 lower doses of CIC (160 g qd) and FP (HFA-MDI, 88 g bid) administered for 12 weeks were equally effective in improving FEV 1 , FVC, peak expiratory flow, asthma symptoms, and the use of rescue medication in 529 adult asthma patients having baseline FEV 1 percent predicted values of 50 to 90% at baseline and not receiving ICSs at baseline.
In summary, these data support the finding that CIC administered at doses of up to 1,280 g/d does not result in a statistically significant suppression of HPA-axis function in patients with moderate-to-severe asthma. Data from this study also indicate that, compared with PBO, there was a statistically significant adrenal suppression following treatment with FP, 1,760 g/d, but not FP, 880 g/d. The absence of the suppression of HPA-axis function with CIC was paralleled by its good tolerability.
